Overall verdict
Neutral
4.5/10
1-year performance
-53.22%
Score breakdown
Down 53.2% over 1 year, 13% of the 52-week range.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Joel Lewis
Founded
2000
Employees
9
Revenue / employee
0 USD
Next earnings
March 31, 2027 (estimated)
Institutional holders
- BlackRock, Inc.3.35%
- GEODE CAPITAL MANAGEMENT, LLC1.24%
- STATE STREET CORP0.79%
- GOLDMAN SACHS GROUP INC0.14%
- MORGAN STANLEY0.13%
- RENAISSANCE TECHNOLOGIES LLC0.11%
- Bank of New York Mellon Corp0.11%
- JPMORGAN CHASE & CO0.04%
- FMR LLC0.02%
- Rest of the register94.09%
9 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
7.13 USD
52-week low
2.02 USD
1-year performance
-53.22%
Declining
Year-to-date performance
-35.95%
Declining
Drawdown
-62.27%
Major drawdown
Position in the 52-week range
13% of range
Against the world ETF
Over 24 years, from September 2002 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 7.8 times harder.
$10,000 placed at the end of September 2002 are worth today
| Galectin | $1,627 |
| World ETF | $101,432 |
| S&P 500 | $142,884 |
| Risk-free placement | $15,172 |
The risk
- Shaking:the share moves 7.8 times as much as the world ETF.
- Worst fall:-98 % between September 2003 and December 2008. $10,000 placed at the top fell to $164. The world ETF, at worst: -53 %. The share has not returned to its high yet.
Galectin earned less than the world ETF since 2002
Value of $10,000 placed at the end of September 2002, dividends reinvested, in dollars
- Galectin: $1,627
- World ETF: $101,432
- S&P 500: $142,884
- Risk-free placement: $15,172
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
ROIC -271.7%, ROE 28.9%.
Net margin
—
Sector -213.59%|S&P 13.35%
Gross margin
—
Return on equity (ROE)
28.90%
High
Sector -55.61%|S&P 16.98%
Return on invested capital (ROIC)
-271.74%
Negative
Free cash flow margin (FCF)
—
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.38|S&P 0.84
Market cap
271M USD
Financial strength
2.4/10Cash covers 35.2% of the debt.
Net debt / EBITDA
—
Gearing (net debt / equity)
—
Cash
11.7M USD
Cash / market cap
4.31%
Tight
Cash / total debt
35.18%
Solid
Interest coverage
-2.2x
Stretched
Net debt
21.6M USD
Equity
-33.4M USD
Closed daily candles, 2 years
Last close on November 20, 2026: 2.69 USD
- MM203.20
- MM503.53
- MM2003.21
- RSI 1432.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.27%
200-day average slope, 3 months
-8.36%
50-day average slope, 1 month
-8.10%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
5.15 % per day
Volatility change
-3.54%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.26 (1) | — | 0 (1) | -15 (1) | -21 (1) |
| 2027 | -0.16 (1) | — | 0 (1) | -17 (1) | -17 (1) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 16, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | GALT | 4.5 | N/A | 271M USD | Not meaningful (loss) | — | — | -271.7 % | — | -5.4 % | -53.2 % | ||
| 3 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 4 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 5 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 6 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 7 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 8 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
